Clinical Trials Directory

Trials / Completed

CompletedNCT06816355

Exogenous Sex Hormones and PONV

Exogenous Sex Hormones and PONV: Evaluating Postoperative Nausea and Vomiting Risk in Transgender Patients

Status
Completed
Phase
Study type
Observational
Enrollment
7,348 (actual)
Sponsor
Riverside University Health System Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).

Detailed description

A retrospective cohort study will be performed using the TriNetX database. Cohorts were defined using Common Procedural Terminology and International Classification of Diseases-10 codes. Separate analyses will be performed for hysterectomies, orchiectomies, and augmentation mammoplasties. Patients will be excluded if they had a history of postoperative nausea and vomiting or a history of neoplasm for which the respective procedure would be indicated (e.g., uterine, cervical, testicular, or breast cancer). Transgender patients will be excluded if not on exogenous hormone therapy and cisgender patients will be excluded if on the same exogenous hormone therapy as their transgender counterparts. Patients will be divided into two groups (transgender group and cisgender group) based on whether they had a diagnosis of sex reassignment, transsexualism, or gender identity disorder. The cohorts will be propensity score-matched based on age, race/ethnicity, and tobacco use.

Conditions

Interventions

TypeNameDescription
PROCEDUREOrchiectomyCPT:54520
PROCEDUREHysterectomyCPT:1013911
PROCEDUREAugmentation mammoplastyCPT:19325

Timeline

Start date
2025-02-04
Primary completion
2025-02-04
Completion
2025-02-04
First posted
2025-02-10
Last updated
2025-02-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06816355. Inclusion in this directory is not an endorsement.